The prevalence of measles seropositivity and antibody responses of seronegative cases in childhood 2-14 YAS GRUBU COCUKLARDA KIZAMIK SEROPREVALANSI VE SERONEGATIF OLGULARIN ASI YANITI
Bulletin of Gulhane Military Medical Academy, cilt.37, sa.1, ss.22-30, 1995 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 37 Sayı: 1
- Basım Tarihi: 1995
- Dergi Adı: Bulletin of Gulhane Military Medical Academy
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.22-30
- Anahtar Kelimeler: Childhood, Measles, Prevalence
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
This study was performed to investigate the prevalence of measles seropositivity in children who were not infected with virus and immunized measles vaccine at different ages. In addition, in present study aimed at determining the antibody responses of seronegative cases after reimmunization and providing a new data for national vaccination schedule. Two hundred and ninety healthy children aged 2 to 14 years were included in the study. They were grouped according to their demographic characteristics, the duration between vaccination and the beginning of the study, and the age that they were vaccinated. Measles IgG titers of children were measured quantitatively. The children with lower measles IgG levels than cut-off values were revaccinated. Measles IgM and IgG were tested two weeks after revaccination. The rates of serpositivity revealed no significant difference between the groups which are classified according to their demographic characteristics and the time from vaccination to the beginning of the study (p > 0.05). The prevalence of seronegativity in cases vaccinated before 12 months of age were significantly high (p < 0.05). In those cases, the seronegativity rate in 4-6 years old group were higher than the other age groups (% 39.6). We conclude that measles vaccine should be given routinely to children at 12 months of age and after, again to children when they enter junior school except for the outbreaks and increased local incidence. This strategy prevents the children against reduced secondary vaccine immunization, provides high rates of vaccination, and reduces the rates of primary vaccination failure.